Literature DB >> 28059670

Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.

Pryscilla Fanini Wowk1, Luís Henrique Franco1, Denise Morais da Fonseca1, Marina Oliveira Paula1, Élcio Dos Santos Oliveira Vianna2, Ana Paula Wendling3, Valéria Maria Augusto4, Silvana Maria Elói-Santos4, Andréa Teixeira-Carvalho3, Flávia Dias Coelho Silva5, Solange Alves Vinhas5, Olindo Assis Martins-Filho3, Moisés Palaci5, Célio Lopes Silva1, Vânia Luiza Deperon Bonato1.   

Abstract

Previously we showed that 65-kDa Mycobacterium leprae heat shock protein (Hsp65) is a target for the development of a tuberculosis vaccine. Here we evaluated peripheral blood mononuclear cells (PBMC) from healthy individuals or tuberculosis patients stimulated with two forms of Hsp65 antigen, recombinant DNA that encodes Hsp65 (DNA-HSP65) or recombinant Hsp65 protein (rHsp65) in attempting to mimic a prophylactic or therapeutic study in vitro, respectively. Proliferation and cytokine-producing CD4+ or CD8+ cell were assessed by flow cytometry. The CD4+ cell proliferation from healthy individuals was stimulated by DNA-HSP65 and rHsp65, while CD8+ cell proliferation from healthy individuals or tuberculosis patients was stimulated by rHSP65. DNA-HSP65 did not improve the frequency of IFN-gamma+ cells from healthy individuals or tuberculosis patients. Furthermore, we found an increase in the frequency of IL-10-producing cells in both groups. These findings show that Hsp65 antigen activates human lymphocytes and plays an immune regulatory role that should be addressed as an additional antigen for the development of antigen-combined therapies.

Entities:  

Keywords:  IFN-γ; IL-10; tuberculosis; vaccine

Mesh:

Substances:

Year:  2017        PMID: 28059670      PMCID: PMC5443371          DOI: 10.1080/21645515.2016.1264547

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  52 in total

1.  IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway.

Authors:  A Joss; M Akdis; A Faith; K Blaser; C A Akdis
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

Review 2.  Mechanisms of MHC class I-restricted antigen processing and cross-presentation.

Authors:  Peter Cresswell; Anne L Ackerman; Alessandra Giodini; David R Peaper; Pamela A Wearsch
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

3.  Clinical correlates of interferon gamma production in patients with tuberculosis.

Authors:  A Sodhi; J Gong; C Silva; D Qian; P F Barnes
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

4.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

5.  Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy.

Authors:  C S Hirsch; Z Toossi; C Othieno; J L Johnson; S K Schwander; S Robertson; R S Wallis; K Edmonds; A Okwera; R Mugerwa; P Peters; J J Ellner
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

6.  IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis.

Authors:  K F Hoffmann; A W Cheever; T A Wynn
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

Review 7.  TB drug development: immunology at the table.

Authors:  Carl Nathan; Clifton E Barry
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

8.  Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.

Authors:  Eduardo D C Gonçalves; Vânia Luiza D Bonato; Denise M da Fonseca; Edson G Soares; Izaíra T Brandão; Ana Paula M Soares; Célio L Silva
Journal:  Genet Vaccines Ther       Date:  2007-08-22

9.  Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.

Authors:  Steven G Smith; Kaatje Smits; Simone A Joosten; Krista E van Meijgaarden; Iman Satti; Helen A Fletcher; Nadia Caccamo; Francesco Dieli; Francoise Mascart; Helen McShane; Hazel M Dockrell; Tom H M Ottenhoff
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

Review 10.  A review of clinical models for the evaluation of human TB vaccines.

Authors:  Matthew K O'Shea; Helen McShane
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

View more
  2 in total

1.  Identification of antigens presented by MHC for vaccines against tuberculosis.

Authors:  Julius Müller; Annalisa Nicastri; Daire Cantillon; Nicola Ternette; Helen McShane; Paulo Bettencourt; Meera Madhavan; Philip D Charles; Carine B Fotso; Rachel Wittenberg; Naomi Bull; Nawamin Pinpathomrat; Simon J Waddell; Elena Stylianou; Adrian V S Hill
Journal:  NPJ Vaccines       Date:  2020-01-03       Impact factor: 7.344

Review 2.  Immunotherapeutic Activities of a DNA Plasmid Carrying the Mycobacterial hsp65 Gene (DNAhsp65).

Authors:  Celio Lopes Silva; Thiago Malardo; Aline Seiko Carvalho Tahyra
Journal:  Front Med Technol       Date:  2020-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.